Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

S. Soverini, C. De Benedittis, KM. Polakova, J. Linhartova, F. Castagnetti, G. Gugliotta, C. Papayannidis, M. Mancini, H. Klamova, M. Salvucci, M. Crugnola, A. Iurlo, F. Albano, D. Russo, G. Rosti, M. Cavo, M. Baccarani, G. Martinelli,

. 2016 ; 7 (16) : 21982-90.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18017330

In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who fail imatinib treatment, BCR-ABL1 mutation profiling by Sanger sequencing (SS) is recommended before changing therapy since detection of specific mutations influences second-generation tyrosine kinase inhibitor (2GTKI) choice. We aimed to assess i) in how many patients who relapse on second-line 2GTKI therapy next generation sequencing (NGS) may track resistant mutations back to the sample collected at the time of imatinib resistance, before 2GTKI start (switchover sample) and ii) whether low level mutations identified by NGS always undergo clonal expansion. To this purpose, we used NGS to retrospectively analyze 60 imatinib-resistant patients (CML, n = 45; Ph+ ALL,n = 15) who had failed second-line 2GTKI therapy and had acquired BCR-ABL1 mutations (Group 1) and 25 imatinib-resistant patients (CML, n = 21; Ph+ ALL, n = 4) who had responded to second-line 2GTKI therapy, for comparison (Group 2). NGS uncovered that in 26 (43%) patients in Group 1, the 2GTKI-resistant mutations that triggered relapse were already detectable at low levels in the switchover sample (median mutation burden, 5%; range 1.1%-18.4%). Importantly, none of the low level mutations detected by NGS in switchover samples failed to expand whenever the patient received the 2GTKI to whom they were insensitive. In contrast, no low level mutation that was resistant to the 2GTKI the patients subsequently received was detected in the switchover samples from Group 2. NGS at the time of imatinib failure reliably identifies clinically relevant mutations, thus enabling a more effective therapeutic tailoring.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017330
003      
CZ-PrNML
005      
20180515103110.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.8010 $2 doi
035    __
$a (PubMed)26980736
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Soverini, Simona $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
245    10
$a Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients / $c S. Soverini, C. De Benedittis, KM. Polakova, J. Linhartova, F. Castagnetti, G. Gugliotta, C. Papayannidis, M. Mancini, H. Klamova, M. Salvucci, M. Crugnola, A. Iurlo, F. Albano, D. Russo, G. Rosti, M. Cavo, M. Baccarani, G. Martinelli,
520    9_
$a In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who fail imatinib treatment, BCR-ABL1 mutation profiling by Sanger sequencing (SS) is recommended before changing therapy since detection of specific mutations influences second-generation tyrosine kinase inhibitor (2GTKI) choice. We aimed to assess i) in how many patients who relapse on second-line 2GTKI therapy next generation sequencing (NGS) may track resistant mutations back to the sample collected at the time of imatinib resistance, before 2GTKI start (switchover sample) and ii) whether low level mutations identified by NGS always undergo clonal expansion. To this purpose, we used NGS to retrospectively analyze 60 imatinib-resistant patients (CML, n = 45; Ph+ ALL,n = 15) who had failed second-line 2GTKI therapy and had acquired BCR-ABL1 mutations (Group 1) and 25 imatinib-resistant patients (CML, n = 21; Ph+ ALL, n = 4) who had responded to second-line 2GTKI therapy, for comparison (Group 2). NGS uncovered that in 26 (43%) patients in Group 1, the 2GTKI-resistant mutations that triggered relapse were already detectable at low levels in the switchover sample (median mutation burden, 5%; range 1.1%-18.4%). Importantly, none of the low level mutations detected by NGS in switchover samples failed to expand whenever the patient received the 2GTKI to whom they were insensitive. In contrast, no low level mutation that was resistant to the 2GTKI the patients subsequently received was detected in the switchover samples from Group 2. NGS at the time of imatinib failure reliably identifies clinically relevant mutations, thus enabling a more effective therapeutic tailoring.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a mutační analýza DNA $x metody $7 D004252
650    _2
$a dasatinib $x terapeutické užití $7 D000069439
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a bcr-abl fúzní proteiny $x genetika $7 D016044
650    _2
$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x terapeutické užití $7 D000068877
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $7 D015464
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $x genetika $7 D054198
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a De Benedittis, Caterina $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
700    1_
$a Polakova, Katerina Machova $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Linhartova, Jana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Castagnetti, Fausto $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
700    1_
$a Gugliotta, Gabriele $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
700    1_
$a Papayannidis, Cristina $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
700    1_
$a Mancini, Manuela $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
700    1_
$a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Salvucci, Marzia $u Oncology-Hematology Department, "S. Maria delle Croci" Hospital, Ravenna, Italy.
700    1_
$a Crugnola, Monica $u Hematology, Parma University Hospital, Parma, Italy.
700    1_
$a Iurlo, Alessandra $u Division of Haematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
700    1_
$a Albano, Francesco $u Hematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
700    1_
$a Russo, Domenico $u Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
700    1_
$a Rosti, Gianantonio $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
700    1_
$a Cavo, Michele $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
700    1_
$a Baccarani, Michele $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
700    1_
$a Martinelli, Giovanni $u Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 16 (2016), s. 21982-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26980736 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103244 $b ABA008
999    __
$a ok $b bmc $g 1300954 $s 1014170
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 16 $d 21982-90 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options